The new research
The aim of the study is to demonstrate the performance of the neuCA15.3 test for monitoring treatment response and/or disease recurrence compared to an FDA cleared CA15-3 test (Roche Elecys CA15-3 II).
Is anyone expecting any significantly different data - we've already been told specificity and sensitivity %'s - what exactly will the new study tell us?
Ann: Trading Halt, page-12
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
-0.005(0.90%) |
Mkt cap ! $50.61M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 55.0¢ | 54.0¢ | $107.8K | 196.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12706 | 55.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.0¢ | 7600 | 2 |
View Market Depth
| Last trade - 11.38am 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
54.5¢ |
Change
-0.005 ( 2.68 %) |
||||
| Open | High | Low | Volume | ||
| 55.0¢ | 55.0¢ | 54.5¢ | 12903 | ||
| Last updated 11.34am 06/06/2024 ? | |||||
| IIQ (ASX) Chart |